Earnings Call, Conference Presentation
GLP-1s are shrinking some appetites; broader use poses a prickly challenge
- U.S. GLP-1 penetration among non-diabetic obese patients is projected to reach 10% (approx. 10 million individuals) initially, with growth to 13–17% (15–20 million patients) within two to three years, while U.S. revenues are forecast to hit approximately $28 billion in 2026.
- Global revenue distribution is expected to evolve from current U.S. dominance to an eventual 50-50 split, with a future peak sales opportunity potentially shifting to a 60-70% contribution from international markets as adoption there accelerates.
- Oral therapies are anticipated to reduce logistical and social barriers to drive category growth, though a new wave of competitors and generic semi-glutides is expected to enter the market between 2028 and 2029.
- GLP-1 pricing is forecast to remain in a deflationary cycle for the next five years, with lower-income Medicare utilization increasing under Trump agreement fixed price points and cash pay channels showing signs of price sensitivity.
- Patient retention is projected such that approximately 33% discontinue therapy within six months due to cost or tolerability, while 40–45% remain on treatment for over a year, with a core group maintaining long-term use.
- Next-generation drugs targeting side effects are expected to cause modest market share shifts rather than overall market expansion, and analysts suggest investors will favor companies demonstrating innovation over those with undifferentiated pipelines.
- Packaged food sectors face volume weakness driven by pricing challenges and low-income wage stagnation in a K-shaped economy, with sweet treats, salty snacks, and potato chips identified as the most negatively impacted categories.
- Food demand declines are attributed more to excessive pricing by food companies than GLP-1 adoption, though terminal growth rates could see an additional 50 to 100 basis points of negative growth, particularly in packaged fruit.
- Distinct consumer demographics exist between packaged food users and GLP-1 populations due to children's ineligibility, yet yogurt is the only specific food category projected to increase in consumption due to protein content and digestibility.
- Overall household alcohol consumption is expected to remain flat, while wine and spirits consumption may decline among the specific member using the drug, with total volume weakness persisting as long as inflationary pressures remain.